StreetAlpha.app
Home › Stocks › GLUE

Monte Rosa Therapeutics, Inc. (GLUE)

Healthcare
$8.64
▼ −3.03%
LAST CLOSE · NOV 20

Monte Rosa Therapeutics develops small molecule drugs that break down proteins tied to immune disorders and cancers. It last closed at $8.64 on Nov 20, down 3.03% on the day. The next earnings report for GLUE is expected around Tue, Mar 16, 2027. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months GLUE insiders bought $0 of stock on the open market and sold $4.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is GLUE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GLUE.

Key Stats

Last 12 months
Results
Revenue
$70.3M
−61.3% vs a year ago
Net income
−$130.9M
−725.2% vs a year ago
Free cash flow
−$174.4M
−248.0% margin
Operating margin
−214.5%
−$150.8M operating income
Valuation
Market cap
$738.3M
85.5M shares
P/E
–
Price to sales
10.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$45.2M
At Sep 30
Shareholder equity
$496.2M
Shares outstanding
85.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $75.6M$75.6MFY2024FY2025: $123.7M$123.7MFY2025

From GLUE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 16
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$54.4M
+325.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $60.6MDec '24Mar 2025: $84.9MMar '25Jun 2025: $23.2MJun '25Sep 2025: $12.8MSep '25Dec 2025: $2.8MDec '25Mar 2026: $4.2MMar '26Jun 2026: $9.0MJun '26Sep 2026: $54.4MSep '26Latest $54.4M
How GLUE moved after its last 8 reports
Average move the session after a report ±4.3%
Nov 5, 2026Time not announced−5.3%
Aug 6, 2026Time not announced+0.6%
May 7, 2026Time not announced−2.8%
Mar 17, 2026Time not announced−2.0%
Nov 6, 2025Time not announced+5.7%
Aug 7, 2025Time not announced−2.9%
May 8, 2025Time not announced+9.6%
Mar 20, 2025Time not announced+5.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on GLUEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on GLUE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on GLUE

Technical Analysis

GLUE · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 16% below its 20 day and 25% below its 50 day average. It is 91% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $8.48, and the nearest resistance the Pivot at $8.72.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.8%/day
Key levels
$25.7752 week high+198.3%
$16.46200 day average+90.5%
$14.52100 day average+68.1%
$11.20Swing high (Oct 29)+29.6%
$10.7850 day average+24.8%
$10.0620 day average+16.4%
$8.96Pivot R1+3.7%
$8.72Pivot+0.9%
$8.64Last close
$8.4852 week low−1.9%
$8.40Pivot S1−2.8%
Indicators
RSI (14)27.24Oversold below 30Oversold
MACD-0.60Below its signal lineBearish
Stochastic7.8Near the bottom of its rangeOversold
ADX (14)31.7Trending down
Williams %R-93.8Oversold below −80, overbought above −20Oversold
CCI (20)-137.2Oversold below −100, overbought above 100Oversold
Rate of change−18.3%Change over 10 sessionsBearish
ATR (14)$0.59Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GLUE

What happened before

See how GLUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow GLUE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How GLUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for GLUEHow many large options trades hit GLUE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

GLUE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●98 buying vs 103 selling
  • ●Held by funds -0.3 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191195−2.1%
In funds' top 1046−33.3%
Held by funds108.9%109.2%−0.3 pts
New / increased37 / 6129 / 82−11.7%
Reduced / sold out63 / 4059 / 23+25.6%
Put/call ratio0.030.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GLUE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GLUE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.1M31 sales · 8 insiders
54% of the selling was under pre-arranged trading plans.
2026-01 sold $481K2026-02 sold $179K2026-03 sold $565K2026-04 sold $245K2026-05 sold $488K2026-06 sold $1.7M2026-07 sold $462K2026-10 sold $137DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 5Matthew BowenPrincipal Accounting OfficerSale13$10.56$137
Jul 16Markus WarmuthPresident & CEOSale9,500$23.18$220K
Jul 15Jennifer ChampouxCOOSale plan4,351$23.38$102K
Jul 6Sharon TownsonChief Scientific OfficerSale plan6,000$23.31$140K
Jun 30Filip JankuChief Medical OfficerSale plan5,407$24.50$132K
Jun 29Anthony M. ManningDirectorSale10,000$23.11$231K
Every insider buy and sale for GLUE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See GLUE insider trades →

From SEC Form 4 filings by GLUE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GLUE is in one of them and how their past GLUE trades turned out.

GLUE in the AI portfolios
Loading…

GLUE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GLUE in an article yet. Here's the latest on the wider market.

GLUE in the news

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company based in Boston, Massachusetts. It develops small molecule drugs called molecular glue degraders, which use the body's natural protein disposal system to break down proteins tied to disease. Its candidates are in clinical trials for immune conditions, inflammatory diseases, and prostate cancer, and it is developing programs for other cancers. Its main partner is Novartis, which has licensed one of its immune disease programs.

Headquarters
Boston, MA